Table 1.
Clinical descriptors for the TRD and healthy control groups in the structural MRI analysis.
Variables are shown as mean (standard deviation).
Fig 1.
Feature selection (Gaussian SVM) identified brain regions in grey matter.
PV—periventricular grey matter; C—caudate; IN—insula.
Fig 2.
Group-level grey matter reductions in patients with TRD compared with healthy matched controls.
PV- periventricular grey matter, C—caudate reductions, H—habenula and IN—insula.
Fig 3.
Overlapping grey matter regions between features selected during classification (purple/blue) and regions selected in the VBM analysis (red/purple).
Table 2.
Treatment Resistance, State Illness Severity and Current Medication.
No patients had psychotic symptoms and quetiapine was prescribed as an augmentation agent for antidepressants [71], similar to the long established use of lithium, L-tryptophan and tri-iodothyronine in treatment resistant depression. No obvious relationships between current medication and treatment resistance/state illness severity were present. ‘mg’ indicates total dose per day, ‘mcg’ total micrograms per day.